HC Wainwright Cuts Alumis (NASDAQ:ALMS) Price Target to $25.00

Alumis (NASDAQ:ALMS) had its price objective decreased by HC Wainwright from $40.00 to $25.00 in a research note published on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Alumis’ Q1 2026 earnings at ($0.70) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($2.89) EPS and FY2027 earnings at ($3.37) EPS.

ALMS has been the topic of a number of other reports. Morgan Stanley lifted their target price on Alumis from $33.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, March 20th. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Alumis in a report on Tuesday, January 6th. Chardan Capital raised their price objective on Alumis from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Wells Fargo & Company boosted their price objective on Alumis from $17.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday, January 6th. Finally, Loop Capital set a $37.00 target price on Alumis in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alumis has an average rating of “Moderate Buy” and an average target price of $38.60.

Alumis Price Performance

NASDAQ:ALMS opened at $22.73 on Monday. Alumis has a one year low of $2.76 and a one year high of $30.60. The company has a fifty day moving average price of $26.34 and a 200 day moving average price of $14.85. The stock has a market cap of $2.89 billion, a P/E ratio of -7.43 and a beta of -0.61.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.05). Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%.The company had revenue of $1.93 million during the quarter, compared to analyst estimates of $2.75 million. As a group, equities research analysts anticipate that Alumis will post -8.51 EPS for the current year.

Insider Buying and Selling at Alumis

In other Alumis news, Director Srinivas Akkaraju purchased 588,235 shares of the business’s stock in a transaction on Friday, January 9th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $9,999,995.00. Following the completion of the purchase, the director directly owned 1,853,488 shares in the company, valued at approximately $31,509,296. This trade represents a 46.49% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Foresite Labs, Llc acquired 411,764 shares of the firm’s stock in a transaction on Thursday, January 8th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the acquisition, the insider directly owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. This represents a 7.78% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 1,823,527 shares of company stock worth $30,999,959. 40.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alumis

Hedge funds and other institutional investors have recently modified their holdings of the stock. MPM Bioimpact LLC acquired a new stake in Alumis in the 4th quarter valued at $23,443,000. Orbimed Advisors LLC acquired a new position in Alumis during the second quarter worth $5,779,000. Velan Capital Investment Management LP acquired a new position in Alumis during the second quarter worth $4,863,000. Woodline Partners LP lifted its holdings in shares of Alumis by 809.7% during the third quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock valued at $6,987,000 after acquiring an additional 1,558,660 shares during the period. Finally, Samsara Biocapital LLC boosted its stake in shares of Alumis by 47.0% in the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after purchasing an additional 1,534,872 shares in the last quarter.

Key Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: HC Wainwright raised EPS estimates across Q1–Q4 and lifted FY2026/FY2027 outlooks (e.g., FY2026 from ($2.99) to ($2.89); Q1–Q4 tweaks), while maintaining a “Buy” rating and a $25 price target — this reduces projected losses and provides an analyst-backed upside case. HC Wainwright research coverage (summary)
• Positive Sentiment: Chardan Capital assigned a Buy rating, adding an additional institutional endorsement that can attract buyer interest. Alumis Earns Buy Rating from Chardan Capital
• Positive Sentiment: An Oppenheimer analyst is reported to expect the stock to rise, reinforcing bullish sentiment from multiple brokers and likely supporting demand. Oppenheimer bullish note
• Neutral Sentiment: General market coverage (CNN) lists ALMS among tracked stocks; broad news distribution can increase visibility but doesn’t by itself change fundamentals. CNN: Alumis Inc.
• Neutral Sentiment: A news piece with a contrary headline referencing a “pessimistic forecast” appeared, but the underlying broker actions (above) show upward revisions and Buy ratings — treat the conflicting headlines cautiously. HC Wainwright pessimistic forecast article

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.